Orchard’s MLD gene therapy becomes costliest US medicine
pharmaphorum
MARCH 20, 2024
Orchard Therapeutics has revealed the US price of Lenmeldy, its gene therapy for rare disease MLD, placing a $4.25m price tag on the one-shot treatment
tag orchard-therapeutics 
111 
STAT+: Kyowa Kirin to acquire Orchard Therapeutics, maker of gene therapy Libmeldy
STAT
OCTOBER 5, 2023
LONDON — The Japanese firm Kyowa Kirin is acquiring gene therapy maker Orchard Therapeutics in a $400 million deal, the companies said Thursday. Kyowa Kirin is paying $16 per share — a nearly 100% premium on Orchard’s Wednesday closing price — in cash, amounting to roughly $390 million.
Let's personalize your content